<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="450">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370486</url>
  </required_header>
  <id_info>
    <org_study_id>25/10</org_study_id>
    <nct_id>NCT01370486</nct_id>
  </id_info>
  <brief_title>Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects</brief_title>
  <official_title>Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institution de Lavigny</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institution de Lavigny</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lennox-Gastaut syndrome is a severe epileptic encephalopathy of childhood. In that syndrome,
      various type of seizure occur, mainly tonic seizures, atonic seizures and atypical absences.
      The tonic seizure occur mostly at night.

      The hypothesis is that the melatonin could have a positive effect in that syndrome, by
      reducing the epileptic activity (assessed in the polysomnographic record by counting the
      number of interictal and ictal discharges) and stabilizing the structure of sleep.

      The study is double blind, randomised, cross-over designed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the trial is to study the efficacity of melatonin in the Lennox-Gastaut syndrome,
      by assessing the reduction of the seizure/interictal discharges in polysomnography and
      assessing the sleep structure.

      After initial recruitment, the baseline visit includes a polysomnography. The patients will
      then be randomised in two groups: melatonin (1 cp containing melatonin 2 mg 1x/d 1h before
      sleep) vs placebo (1 cp 1x/d 1h before sleep). The treatment (melatonin or placebo) will be
      given for 1 month.

      After 1 month, the treatment will be stopped and another polysomnography will be recorded.

      The patients will take no treatment (wash-out period) for 15 days. The second treatment
      phase is cross-over: the group that had melatonin in the first phase will take placebo for
      one month, and the group that had placebo in the first treatment phase will take melatonin
      for one month. A last polysomnography will be recorded after the second treatment phase.

      The other medications (antiepileptic drugs) taken by the patients before the trial will not
      be modified.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>diminution of at least 50% of the nocturnal interictal discharges and tonic seizures with the melatonin treatment</measure>
    <time_frame>assessed after 1 month and 2.5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The patients will have three polysomnographic recording: at the baseline, one month after initiating the treatment (melatonin or placebo) and one month after the cross-over phase. The number of tonic seizure and if interictal discharges will be assessed.
The primary outcome measure is a diminution of &gt; 50% of the seizures/interictal discharges with the melatonin treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>augmentation of at least 15% of the amount of deep slow sleep with the melatonin treatment</measure>
    <time_frame>assessed after 1 month and 2.5 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The structure of sleep will be measured with the polysomnography (at baseline, after 1 month and after 2.5 months.
The outcome measure is an augmentation of at least 15% of the deep slow sleep.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Lennox-Gastaut Syndrome</condition>
  <arm_group>
    <arm_group_label>melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>melatonin cp 2 mg 1x/d for 1 month</description>
    <arm_group_label>melatonin</arm_group_label>
    <other_name>brand name: circadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo cp 1x/d for 1 month</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lennox-Gastaut syndrome (based on ILAE classification, 1989)

          -  light mental retardation (QI 50-69)

          -  french mother tongue

          -  having someone helping the patient (parent and/or referent educator)

          -  informed consent have been given by the patient / guardian

          -  absence of concomitant evolutive affection or associated sleep pathologies

          -  collaboration of the patient, ability to complete all aspects of the trial.

        Exclusion Criteria:

          -  epileptic syndrome other than Lennox-Gastaut, other neurologic and/or psychiatric
             disease

          -  moderate to severe mental retardation (QI &lt; 50)

          -  psychiatric disease that could interfere with the diagnostic procedure

          -  specific sleep disorder (anamnestic and diagnosed on the polygraphic record), for
             example: sleep apnea syndrome, narcolepsy, restless legs syndrome, periodic legs
             movements, etc...
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni B. Foletti, MD, MER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institution de Lavigny</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni B. Foletti, MD, MER</last_name>
    <phone>++ 41 21 821 46 46</phone>
    <email>giovanni.foletti@ilavigny.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institution de Lavigny</name>
      <address>
        <city>Lavigny</city>
        <state>Vaud</state>
        <zip>1175</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni B. Foletti, Dr, MD, MER</last_name>
      <phone>++ 41 21 821 46 46</phone>
      <email>giovanni.foletti@ilavigny.ch</email>
    </contact>
    <contact_backup>
      <last_name>Noëlle I. Mercier, Dr.</last_name>
      <phone>++ 41 21 821 41 11</phone>
      <email>noelle.mercier@ilavigny.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni B. Foletti, Dr, MD, MER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sforza Emilia, Dr. , MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noëlle Mercier, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 9, 2011</lastchanged_date>
  <firstreceived_date>June 8, 2011</firstreceived_date>
  <responsible_party>
    <name_title>M. Antonio Gallo, financial manager</name_title>
    <organization>Institution de Lavigny</organization>
  </responsible_party>
  <keyword>Lennox-Gastaut syndrome</keyword>
  <keyword>Epileptic encephalopathy</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Tonic seizures</keyword>
  <keyword>Interictal discharges</keyword>
  <keyword>Quality of sleep</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
